Archford Capital Strategies LLC increased its holdings in shares of Eli Lilly and Co (NYSE:LLY) by 26.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,076 shares of the company’s stock after purchasing an additional 1,676 shares during the period. Archford Capital Strategies LLC’s holdings in Eli Lilly and were worth $690,000 as of its most recent SEC filing.
A number of other large investors have also modified their holdings of LLY. Kovitz Investment Group Partners LLC increased its holdings in Eli Lilly and by 2.1% during the 1st quarter. Kovitz Investment Group Partners LLC now owns 7,450 shares of the company’s stock valued at $627,000 after acquiring an additional 151 shares in the last quarter. OLD Mutual Customised Solutions Proprietary Ltd. boosted its stake in shares of Eli Lilly and by 18.2% during the 1st quarter. OLD Mutual Customised Solutions Proprietary Ltd. now owns 15,482 shares of the company’s stock worth $1,302,000 after purchasing an additional 2,382 shares during the last quarter. First Financial Equity Corporation acquired a new stake in shares of Eli Lilly and during the 1st quarter worth about $252,000. Janus Capital Management LLC boosted its stake in shares of Eli Lilly and by 2.8% during the 1st quarter. Janus Capital Management LLC now owns 8,723,692 shares of the company’s stock worth $733,731,000 after purchasing an additional 237,619 shares during the last quarter. Finally, Salem Investment Counselors Inc. boosted its stake in shares of Eli Lilly and by 23.3% during the 1st quarter. Salem Investment Counselors Inc. now owns 35,800 shares of the company’s stock worth $3,015,000 after purchasing an additional 6,754 shares during the last quarter. Hedge funds and other institutional investors own 76.31% of the company’s stock.
Eli Lilly and Co (NYSE LLY) traded up $0.59 during mid-day trading on Friday, reaching $86.98. 2,728,878 shares of the company’s stock traded hands, compared to its average volume of 3,260,000. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. Eli Lilly and Co has a 12-month low of $74.00 and a 12-month high of $89.09. The company has a market capitalization of $95,770.00, a price-to-earnings ratio of 41.42, a price-to-earnings-growth ratio of 1.62 and a beta of 0.35.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.02. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The company had revenue of $5.66 billion during the quarter, compared to the consensus estimate of $5.52 billion. During the same quarter in the previous year, the company posted $0.88 earnings per share. The company’s revenue for the quarter was up 9.0% compared to the same quarter last year. equities research analysts predict that Eli Lilly and Co will post 4.22 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be issued a $0.5625 dividend. The ex-dividend date is Wednesday, February 14th. This represents a $2.25 annualized dividend and a yield of 2.59%. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s dividend payout ratio is presently 99.05%.
Several equities research analysts have issued reports on the stock. Morgan Stanley set a $86.00 price target on shares of Eli Lilly and and gave the stock a “hold” rating in a research note on Friday, October 6th. Leerink Swann raised their target price on shares of Eli Lilly and from $92.00 to $93.00 and gave the stock a “market perform” rating in a research report on Monday, October 23rd. BMO Capital Markets set a $73.00 target price on shares of Eli Lilly and and gave the stock a “sell” rating in a research report on Tuesday, October 24th. Credit Suisse Group cut shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and lifted their price target for the company from $84.23 to $88.00 in a research report on Tuesday, October 10th. Finally, Goldman Sachs Group reaffirmed a “buy” rating and set a $95.00 price target (up from $92.00) on shares of Eli Lilly and in a research report on Thursday, October 5th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $92.14.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 200,000 shares of the business’s stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $88.20, for a total value of $17,640,000.00. Following the sale, the insider now directly owns 123,084,104 shares in the company, valued at $10,856,017,972.80. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Susan Mahony sold 36,585 shares of the business’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the completion of the sale, the senior vice president now owns 54,885 shares in the company, valued at $4,729,989.30. The disclosure for this sale can be found here. Insiders sold 251,088 shares of company stock valued at $22,041,236 in the last ninety days. Corporate insiders own 0.20% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Eli Lilly and Co (LLY) Holdings Raised by Archford Capital Strategies LLC” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/01/13/eli-lilly-and-co-lly-position-raised-by-archford-capital-strategies-llc.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.